切换至 "中华医学电子期刊资源库"

中华肺部疾病杂志(电子版) ›› 2022, Vol. 15 ›› Issue (06) : 879 -881. doi: 10.3877/cma.j.issn.1674-6902.2022.06.031

短篇论著

高原肺水肿患者临床特点分析
郭亮1, 何思毅2, 杨毓斌3, 关尚全3, 吴学玲4,(), 李少莹5,()   
  1. 1. 400037 重庆,陆军(第三)军医大学第二附属医院呼吸与危重症医学科
    2. 610083 成都,西部战区总医院心血管外科
    3. 844900 新疆,陆军第950医院感染科
    4. 200127 上海,上海交通大学仁济医院呼吸与危重症医学科
    5. 650032 昆明,联勤保障部队第九二〇医院呼吸与危重症医学科
  • 收稿日期:2022-04-17 出版日期:2022-12-25
  • 通信作者: 吴学玲, 李少莹
  • 基金资助:
    联勤保障部队第九二〇医院军事医学研究计划成长项目(2019YGA17)

Analysis of the clinical characteristics of patients with plateau pulmonary edema

Liang Guo1, Siyi He2, Yubin Yang3   

  • Received:2022-04-17 Published:2022-12-25
引用本文:

郭亮, 何思毅, 杨毓斌, 关尚全, 吴学玲, 李少莹. 高原肺水肿患者临床特点分析[J/OL]. 中华肺部疾病杂志(电子版), 2022, 15(06): 879-881.

Liang Guo, Siyi He, Yubin Yang. Analysis of the clinical characteristics of patients with plateau pulmonary edema[J/OL]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(06): 879-881.

高海拔肺水肿(high altitude pulmonary edema, HAPE)是指人们在高海拔环境时,由于环境缺氧导致肺血管收缩和毛细血管通透性增加而引起的高原危重症[1,2,3,4,5]。HAPE的发生主要取决于上升速度、运动强度和绝对海拔高度,尤其是静息时的海拔高度[6]。HAPE的常见症状包括呼吸困难、运动不耐受、疲劳、咳嗽和发绀等。如救治不及,HAPE患者的病死率可达50%[7],如果出现合并症,病死率升高。HAPE的并发症包括肺炎、高原脑水肿(high-altitude cerebral edema, HACE)、肺栓塞和脑梗死[8,9,10,11]。尽管HAPE合HACE在急性高原病中并不常见[12],本文收集的资料中,36例HAPE患者,6例合并HACE。本文回顾性分析HAPE患者的临床特征,报道如下。

图1 高原肺水肿的胸部CT表现;注:A、B:为双侧肺水肿;C、D:为单侧肺水肿
表1 HAPE合并HACE患者和HAPE患者血常规、生化指标及凝血功能差异性分析
1
Das BB, Wolfe RR, Chan KC, et al. High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude[J]. Arch Pediatr Adolesc Med, 2004158: 1170-1176.
2
Swenson ER, Bartsch P. High-altitude pulmonary edema[J]. Compr Physiol, 2012, 2: 2753-2773.
3
Woods P, Alcock J. High-altitude pulmonary edema[J]. Evol Med Public Health, 2021, 9(1): 118-119.
4
Walker C, Miner B, Bolotin T. High-Altitude Pulmonary Edema in Ohio at an Elevation of 339 Meters[J]. Open Access Emerg Med, 2021, 13: 151-153.
5
Mulchrone A, Moulton H, Eldridge MW, et al. Susceptibility to high-altitude pulmonary edema is associated with increased pulmonary arterial stiffness during exercise[J]. J Appl Physiol (1985), 2020, 128(3): 514-522.
6
Bartsch P, Mairbaurl H, Swenson ER, et al. High altitude pulmonary oedema[J]. Swiss Med Wkly, 2003, 133(27-28): 377-384.
7
Woods P, Alcock J. High-altitude pulmonary edema[J]. Evol Med Public Health, 2021, 9(1): 118-119.
8
Li Y, Zhang Y, Zhang Y. Research advances in pathogenesis and prophylactic measures of acute high altitude illness[J]. Respir Med, 2018145: 145-152.
9
Lopez JI, Holdridge A, Mendizabal JE. Altitude headache[J]. Curr Pain Headache Rep, 2013, 17(12): 383.
10
Hultgren HN. High altitude pulmonary edema: hemodynamic aspects[J]. Int J Sports Med, 1997, 18(1): 20-25.
11
Clarke C. Acute mountain sickness: medical problems associated with acute and subacute exposure to hypobaric hypoxia[J]. Postgrad Med J, 2006, 82(973): 748-753.
12
Hackett PH, Oelz O. The Lake Louise consensus on definition and quantification of altitude illness. In: Sutton JR, Coates G, Houston CS, eds. Hypoxia: Mountain Medicine. Burlington VT: Queen City Press; 1992: 327-330.
13
Luks AM, Swenson ER, Bartsch P. Acute high-altitude sickness[J]. Eur Respir Rev, 2017, 26(143): 160096.
14
Bärtsch P, Swenson ER. Clinical practice: acute high-altitude illnesses [J]. N Engl J Med, 2013, 368: 2294-2302.
15
Gudbjartsson T, Sigurdsson E, Gottfredsson M, et al. High altitude illness and related diseases-a review[J]. Laeknabladid, 2019, 105(11): 499-507.
16
Zubieta-Calleja GR, Zubieta-DeUrioste N. High altitude pulmonary edema, high altitude cerebral edema, and acute mountain sickness: an enhanced opinion from the high andes-la paz, bolivia 3,500 m[J]. Rev Environ Health, 2022.doi: 10.1515/reveh-2021-0172.
17
Eduardo P, Samia El A, Patricia S, et al. Oxidative stress and diseases associated with high-altitude exposure[J]. Antioxidants (Basel), 2022, 11(2): 267.
18
Joyce KE, Lucas SJE, Imray CHE, et al. Advances in the available non-biological pharmacotherapy prevention and treatment of acute mountain sickness and high altitude cerebral and pulmonary oedema[J]. Expert Opin Pharmacother, 19(17): 1891-1902.
19
Wu J, Han X, Ke H, et al. Pulmonary embolism at extreme high altitude: A study of seven cases[J]. High Alt Med Biol, 2022, 23(3): 209-214.
20
Simko LC, Culleiton AL. Uncommon causes of noncardiogenic pulmonary edema[J]. Nurse Pract, 2020, 45(4): 26-32.
21
Luks AM, Swenson ER. COVID-19 Lung Injury and High-Altitude Pulmonary Edema. A False Equation with Dangerous Implications[J]. Ann Am Thorac Soc, 2020, 17(8): 918-921.
22
Ferguson SK, Pak DI, Hopkins JL, et al. Pre-clinical assessment of a water-in-fluorocarbon emulsion for the treatment of pulmonary vascular diseases[J]. Drug Deliv2019, 26(1): 147-157.
23
Pennardt A. High-altitude pulmonary edema: diagnosis, prevention, and treatment[J]. Curr Sports Med Rep, 2013, 12(2): 115-119.
24
Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update[J]. Wilderness Environ Med, 2014, 25(4Suppl): S4-S14.
25
Pollard AJ, Niermeyer S, Barry P, et al. Children at high altitude: an international consensus statement by an adhoc committee of the international society for mountain medicine[J]. High Alt Med Biol, 2001, 2: 389-403.
[1] 吴姗姗, 潘裕民, 刘晋, 张劲松, 乔莉. 睡眠呼吸暂停综合征患者静脉血栓栓塞症发生率的Meta分析[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(04): 312-317.
[2] 姚金含, 王伟娜, 张玉泉. 妊娠相关深静脉血栓形成患者的预后研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(04): 367-373.
[3] 李世杰, 申传安. 烧伤合并吸入性损伤患者呼吸机相关肺炎的研究现状[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(04): 351-355.
[4] 张胜伟, 孟召路, 热汗古丽·吾休尔, 万世森, 闫鹏, 阳乔. 肺炎支原体诱发反应性感染性皮疹黏膜疹一例[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 309-313.
[5] 郑宝英, 黄小兰, 贾楠, 朱春梅. 儿童难治性肺炎支原体肺炎早期预警指标[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(04): 215-221.
[6] 徐保平, 彭怀文, 喻怀斌, 王晓涛. 新型冠状病毒肺炎继发糖尿病酮症酸中毒合并肝门静脉积气一例[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(04): 250-255.
[7] 张春玉, 陈海云, 肖忠萍, 罗琴, 潘运昌. 血清NT-proBNP 预测肺栓塞心脏功能障碍的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 805-808.
[8] 胡菊英, 李银华, 洪兰, 王宏勇, 丁先军, 李承美, 谭心海. 儿童感染大叶性肺炎与支气管肺炎临床特征分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 813-816.
[9] 晏彦, 杨军, 周凤兰, 孙登昆, 陈玉. 哌拉西林他唑巴坦和哌拉西林舒巴坦治疗细菌性肺炎的倾向性匹配分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 817-819.
[10] 于燕兴, 梅喜庆, 刘凤娟, 于梓薇, 许亚慧, 徐飞. 高通量测序重症肺炎肺泡灌洗液病原体的临床应用[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 785-788.
[11] 刘雯, 赵明栋, 夏伟, 潘以雄. 不同剂量比阿培南治疗重症肺炎的疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 789-792.
[12] 刘春军, 严方方, 王宝锋, 常婷婷, 郭红红, 李志强. 替加环素联合人免疫球蛋白治疗XDRAB致VAP 的疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 797-800.
[13] 燕红玲, 王岩岩, 陈树斌. PCT、NLR联合LUBS预测ICU CRKP致呼吸机相关肺炎撤机及预后分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 617-620.
[14] 杨东星, 沈鹏, 赵慧颖. 免疫球蛋白联合依库珠单抗治疗GBS 并发重度ARDS 患者一例[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 404-408.
[15] 段伟, 刘飞, 许光源, 程宇豪, 陈星. 食管癌调强放疗计划剂量学参数差异对放射性肺炎发生及严重程度的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(04): 320-324.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?